Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21438176 | 0.81 | KLKB1 (0.41) | KLKB1F2 | |
| SCHEMBL21455353 | 0.78 | ATR (0.44) | KLKB1SSTR4 | |
| SCHEMBL31330611 | 0.78 | EGLN1 (0.42) | TET2TSHREGLN1 | |
| SCHEMBL26693812 | 0.72 | KMT2A (0.41) | KLKB1 | |
| SCHEMBL27170354 | 0.71 | WDR5 (0.45) | KLKB1F2 | |
| SCHEMBL9455832 | 0.71 | ALDH1A1 (0.41) | KLKB1SSTR4 | |
| SCHEMBL21355260 | 0.70 | KLKB1 (0.35) | KLKB1 | |
| SCHEMBL29724046 | 0.70 | KLKB1 (0.35) | KLKB1 | |
| SCHEMBL30713271 | 0.69 | TSHR (0.36) | TET2TSHREGLN1 | |
| SCHEMBL29277569 | 0.69 | TSHR (0.36) | TET2TSHREGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159746-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | KLKB1 4832/4885F2 4883/4885SSTR4 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.